Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia. The expansion of mutant BCR-ABL-positive clones under selective pressure of tyrosine kinase inhibition is referred to as clonal selection; there a...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil, Thomas Ernst, Thomas Schenk, Christian Lorentz, Uwe Schwindel, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2011-03-01
Online Access:	https://haematologica.org/article/view/5897